BI-4142   Click here for help

GtoPdb Ligand ID: 12164

Synonyms: BI4142 | compound 8 [PMID: 35883003] | example L-1 [WO2021156178A1] [1]
Compound class: Synthetic organic
Comment: BI-4142 is an oral HER2 selective inhibitor [2]. It inhibits proliferation of Ba/F3 cancer cells with wild-type and activating exon 20 mutation HER2YVMA. EGFR signalling via the EGFR receptor is not altered by BI-4142. BI-4142 is being developed for potential to treat advanced non-small cell lung cancer with oncogenic alterations in Exon 20 of the ERBB2 gene.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 105.91
Molecular weight 467.22
XLogP 2.59
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1cc(ccc1Oc1ccc2c(c1)ncn2C)Nc1ncnc2c1nc(nc2)N1CCNCC1
Isomeric SMILES Cc1cc(ccc1Oc1cc2c(n(cn2)C)cc1)Nc1c2c(ncn1)cnc(n2)N1CCNCC1
InChI InChI=1S/C25H25N9O/c1-16-11-17(3-6-22(16)35-18-4-5-21-19(12-18)30-15-33(21)2)31-24-23-20(28-14-29-24)13-27-25(32-23)34-9-7-26-8-10-34/h3-6,11-15,26H,7-10H2,1-2H3,(H,28,29,31)
InChI Key GBSWEJRAVNWKCB-UHFFFAOYSA-N
References
1. Wilding B, Boese D, Engelhardt H, Fuchs J, Neumueller R, Petronczki M, Scham D, Treu M. (2021)
[1,3]diazino[5,4-d]pyrimidines as her2 inhibitors.
Patent number: WO2021156178A1. Assignee: Boehringer Ingelheim International Gmbh. Priority date: 03/02/2020. Publication date: 12/08/2021.
2. Wilding B, Scharn D, Böse D, Baum A, Santoro V, Chetta P, Schnitzer R, Botesteanu DA, Reiser C, Kornigg S et al.. (2022)
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Nat Cancer, 3 (7): 821-836. [PMID:35883003]